Indeed, the findings from REPRIEVE, a population with low to moderate predicted risk, are consistent with findings in high-risk non-HIV populations, linking hs-cTnI or T to vulnerable plaque.7, 8, 9 The use of hs-cTnT levels to augment identification of high-risk subclinical coronary disease needs to be put in clinical context. This evidence concerns the gene TNNI3 and coronary artery disorder.